Notice for maribavir (Takeda Pharmaceuticals Australia Pty Ltd)
Active ingredients
maribavir
Date of review outcome
Lapse date
Type
Priority Review
Indication
For the treatment of adults with post-transplant CMV infection and disease resistant or refractory to one or more prior therapies
Therapeutic area
Infectious diseases